Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Mechanism and novel therapeutic approaches to wasting in chronic disease.

Ebner N, Springer J, Kalantar-Zadeh K, Lainscak M, Doehner W, Anker SD, von Haehling S.

Maturitas. 2013 Jul;75(3):199-206. doi: 10.1016/j.maturitas.2013.03.014. Epub 2013 May 9. Review.

PMID:
23664695
2.

Novel approaches to the treatment of cachexia.

Argilés JM, López-Soriano FJ, Busquets S.

Drug Discov Today. 2008 Jan;13(1-2):73-8. doi: 10.1016/j.drudis.2007.10.008. Epub 2007 Nov 26. Review.

PMID:
18190867
3.

Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.

Gullett NP, Hebbar G, Ziegler TR.

Am J Clin Nutr. 2010 Apr;91(4):1143S-1147S. doi: 10.3945/ajcn.2010.28608E. Epub 2010 Feb 17. Review.

4.

The pharmacological treatment of cachexia.

Argilés JM, Almendro V, Busquets S, López-Soriano FJ.

Curr Drug Targets. 2004 Apr;5(3):265-77. Review.

PMID:
15058312
5.

The cancer anorexia-cachexia syndrome.

Nelson KA.

Semin Oncol. 2000 Feb;27(1):64-8. Review.

PMID:
10697022
6.

The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.

Koopman R, Ryall JG, Church JE, Lynch GS.

Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):601-6. doi: 10.1097/MCO.0b013e3283318a25. Review.

PMID:
19741516
7.

The pathophysiology of cachexia in chronic obstructive pulmonary disease.

Schols AM, Gosker HR.

Curr Opin Support Palliat Care. 2009 Dec;3(4):282-7. doi: 10.1097/SPC.0b013e328331e91c. Review.

PMID:
19713853
8.

Ghrelin: from discovery to cancer cachexia therapy.

Molfino A, Formiconi A, Rossi Fanelli F, Muscaritoli M.

Curr Opin Clin Nutr Metab Care. 2014 Sep;17(5):471-6. doi: 10.1097/MCO.0000000000000075. Review.

PMID:
24905862
9.

Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia.

Nagaya N, Kojima M, Kangawa K.

Intern Med. 2006;45(3):127-34. Epub 2006 Mar 1. Review.

10.

Nutritional abnormalities contributing to cachexia in chronic illness.

Witte KK, Clark AL.

Int J Cardiol. 2002 Sep;85(1):23-31. Review.

PMID:
12163207
11.

Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach.

Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS.

Ital Heart J. 2003 Apr;4(4):232-5. Review.

PMID:
12784775
12.

Clinical application of ghrelin.

Strasser F.

Curr Pharm Des. 2012;18(31):4800-12. Review.

PMID:
22632860
13.

Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.

Burckart K, Beca S, Urban RJ, Sheffield-Moore M.

Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):410-6. doi: 10.1097/MCO.0b013e328339fdd2. Review.

14.

Pathophysiology of peripheral muscle wasting in cardiac cachexia.

Filippatos GS, Anker SD, Kremastinos DT.

Curr Opin Clin Nutr Metab Care. 2005 May;8(3):249-54. Review.

PMID:
15809526
15.

Using megestrol acetate to ameliorate protein-energy wasting in chronic kidney disease.

Smith CS, Logomarsino JV.

J Ren Care. 2016 Mar;42(1):53-9. doi: 10.1111/jorc.12138. Epub 2015 Nov 5. Review.

PMID:
26537025
16.

Acylated and unacylated ghrelin administration to blunt muscle wasting.

Reano S, Graziani A, Filigheddu N.

Curr Opin Clin Nutr Metab Care. 2014 May;17(3):236-40. doi: 10.1097/MCO.0000000000000049. Review.

PMID:
24572833
17.
18.

Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.

Dalton JT, Taylor RP, Mohler ML, Steiner MS.

Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Review.

PMID:
24189892
19.

The role of ghrelin and ghrelin analogues in wasting disease.

Kamiji MM, Inui A.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):443-51. doi: 10.1097/MCO.0b013e328303dee4. Review.

PMID:
18542005
20.

Involuntary weight loss: the forgotten vital sign.

[No authors listed]

J Support Oncol. 2003 Jul-Aug;1(2):142. No abstract available.

PMID:
15352658

Supplemental Content

Support Center